Using its proprietary antibody discovery platforms, Humabs is focused on the discovery and development of next-generation fully human monoclonal antibodies targeted at infectious and inflammatory diseases.
The technologies were developed by professor Antonio Lanzavecchia, the director of the IRB and the scientific founder of Humabs who will be acting as Humabs Chief scientific officer.
The technologies allow the isolation of the rare ones which produce antibodies with a unique specificity.
Humabs currently has more than 200 antibodies in its pre-clinical development pipeline that treat a number of viruses, including Cytomegalovirus, Influenza virus, HIV-1, Dengue virus, Hepatitis B and C viruses and Rabies.
The company has already licensed its group of cytomegalovirus antibodies, to a pharmaceutical company for further development, and is in discussions with a number of potential partners for FI6.